Following a period of stability in the US biologic asthma market, new data reveals hidden opportunities for differentiation and growing prescriber interest in emerging pipeline therapiesEXTON, PA, May ...

Sanofi has not had the success it was hoping for with its oral BTK inhibitors, acquired as part of its $3.7 billion buyout of Principia Biopharma, but can now point to a win for rilzabrutinib in ...

already a $12 billion blockbuster in other indications – as well as Sanofi’s rival oral BTK inhibitor rilzabrutinib, which showed promise in a mid-stage trial and is heading for phase 3 trials ...

Background: A 75-year-old female presented with a 1 month history of nonbloody diarrhea, associated with abdominal cramping and urgency. Her medical history was notable for chronic myelomonocytic ...

Eboni Price-Haywood, MD, MPH, MMM, Xavier Ochsner College of Medicine, and Toni Flowers, PhD, DHL, MBA, LCMC Health, advocate for understanding individual patient circumstances, ultimately leading ...

Visit a quote page and your recently viewed tickers will be displayed here.